Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 69238-2732

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 69238-2732). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Ny Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure (Sacubitril And Valsartan Tablets 1)

Chemical structure diagram showing the molecular structure of the active ingredients Sacubitril and Valsartan. The image includes detailed atom and bond arrangements for both molecules, with some additional notation indicating hydrates and sodium salts.*

FDA Label Image

Figure 7 (Sacubitril And Valsartan Tablets 10)

A dual line graph comparing hazard ratios with 95% confidence intervals for Sacubitril and Valsartan versus enalapril and versus valsartan. The x-axis represents left ventricular ejection fraction percentage at screening, while the y-axis indicates the hazard ratio. Two sets of data are shown for the PARADIGM-HF and PARAGON-HF studies respectively.*

FDA Label Image

24mg-26mg Label (Sacubitril And Valsartan Tablets 11)

Label for Sacubitril and Valsartan Tablets, 24 mg/26 mg strength, film-coated oral tablets. The packaging indicates 60 tablets per container and is labeled Rx only. Manufactured by Harman Finochem Limited and distributed by Amneal Pharmaceuticals LLC. The label includes storage instructions and barcode details.*

FDA Label Image

49mg-51mg Label (Sacubitril And Valsartan Tablets 12)

Sacubitril and Valsartan Tablets 49 mg/51 mg film-coated tablets packaging label. The image shows the drug name, strength, prescription only status, quantity of 60 tablets, and manufacturer information including Amneal Pharmaceuticals LLC and Harman Finochem Limited. Storage instructions and barcode are also visible.*

FDA Label Image

97mg-103mg Label (Sacubitril And Valsartan Tablets 13)

Sacubitril and Valsartan Tablets 97 mg/103 mg film-coated tablets label showing NDC 69238-2733-1. The label indicates a quantity of 60 tablets and states Rx only. The labeler is Amneal Pharmaceuticals LLC, with manufacturing by Harman Finochem Limited in India. Storage instructions and barcode are also visible.*

FDA Label Image

Figure 1 (Sacubitril And Valsartan Tablets 2)

A forest plot chart showing geometric mean ratios and 90% confidence intervals for coadministered drugs including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The x-axis represents change relative to reference, with values ranging approximately from 0.5 to 2. Black circles indicate AUC values, and open circles represent Cmax values.*

FDA Label Image

Figure 2 (Sacubitril And Valsartan Tablets 3)

A chart displaying the geometric mean ratio and 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan in various populations, including renal impairment (mild to severe), hepatic impairment (mild to moderate), age groups (≥65 years/18-45 years), sex (male/female), and ethnic groups (Asian and Caucasian, Black and Caucasian). The x-axis shows change relative to reference ranging from 0.5 to 4.*

FDA Label Image

Figure 3a (Sacubitril And Valsartan Tablets 4)

A line graph titled 'Time to First Occurrence of CV Death or Heart Failure Hospitalizations in PARADIGM-HF' comparing cumulative failure rates (%) over time (days since randomization) between patients treated with Sacubitril/Valsartan tablets and Enalapril. The graph displays Kaplan-Meier estimates with Enalapril showing a higher failure rate than Sacubitril/Valsartan over approximately 1260 days. Risk table data is shown below the graph for both treatments.*

FDA Label Image

Figure 3b (Sacubitril And Valsartan Tablets 5)

A Kaplan-Meier curve titled 'Time to Occurrence of CV Death in PARADIGM-HF' comparing cumulative failure rates (%) over time in days for Sacubitril Valsartan tablets versus Enalapril. The graph shows lower cumulative failure rates for Sacubitril Valsartan tablets. At-risk patient numbers are listed below the time axis for both groups.*

FDA Label Image

Figure 3c (Sacubitril And Valsartan Tablets 6)

A Kaplan-Meier curve titled 'Time to First Occurrence of Heart Failure Hospitalizations in PARADIGM-HF.' It compares cumulative failure rates (%) over time in days since randomization between patients treated with Sacubitril Valsartan tablets and Enalapril. Sacubitril Valsartan shows a lower cumulative failure rate. The graph includes hazard ratio (HR) 0.79 with a 95% confidence interval (0.71, 0.89) and a table of patient risk numbers over time for both treatments.*

FDA Label Image

Figure 4 (Sacubitril And Valsartan Tablets 7)

A forest plot showing hazard ratios with 95% confidence intervals comparing Sacubitril/Valsartan tablets versus Enalapril across various patient subgroups, including age, gender, weight, race, region, NYHA Class, estimated GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP level, hypertension, prior use of ACE inhibitors, ARBs, aldosterone antagonists, hospitalization for heart failure, time since diagnosis, cause of heart failure, and ICD use. The plot visually indicates the comparative risk between the two treatments in these subgroups.*

FDA Label Image

Figure 5 (Sacubitril And Valsartan Tablets 8)

A line graph comparing total heart failure hospitalizations and cardiovascular (CV) death over time in the PARAGON-HF study. It shows mean number of events per 100 patients on the y-axis versus time since randomization in days on the x-axis, with separate lines for Valsartan and Sacubitril and Valsartan, indicating cumulative event rates up to about 1440 days.*

FDA Label Image

Figure 6 (Sacubitril And Valsartan Tablets 9)

A forest plot comparing the rate ratio of clinical outcomes between Sacubitril and Valsartan versus Valsartan alone across various subgroups. The subgroups include age, gender, race, region, diabetic status, LVEF, atrial fibrillation status, NT-proBNP levels, systolic blood pressure, use of MRA, ACEI intolerance, baseline eGFR, and NYHA class. Each subgroup's estimate with 95% confidence intervals is plotted to show comparative efficacy between the two treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.